Gilead Sciences, Inc. announced today that Jacqueline K. Barton, Ph.D., has been appointed to the company’s Board of Directors. She previously served on Gilead’s Scientific Advisory Board from 1989 to 2007.
Dr. Barton is the John G. Kirkwood and Arthur A. Noyes Professor of Chemistry and Norman Davidson Leadership Chair of the Division of Chemistry and Chemical Engineering at the California Institute of Technology, where she has been a faculty member for nearly 30 years. She served on the Board of Directors of the Dow Chemical Company from 1993 to 2017, and currently is a member of the Materials Science Advisory Committee of DowDuPont, Inc. She founded and served on the Board of GeneOhm Sciences, Inc., a molecular diagnostic company acquired by Becton Dickinson and Company. She is a member of the National Academy of Sciences, the National Academy of Medicine and the American Philosophical Society. In 2011, Dr. Barton received the National Medal of Science for her discovery of new chemistry of the DNA helix.
“We are very pleased to welcome Jacqueline Barton to the Board of Directors of Gilead Sciences,” said John Milligan, Ph.D., President and Chief Executive Officer, Gilead Sciences. “Jackie is one of the most decorated chemists in America and was awarded the Priestley Medal from the American Chemical Society, its highest honor. Her deep knowledge of scientific discovery in both academic and industry settings will help guide our long-term strategy as Gilead continues to translate science into better solutions for patients.”
Source: Gilead Sciences
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
